<DOC>
	<DOC>NCT00266123</DOC>
	<brief_summary>To demonstrate the superiority of SRL + TAC elimination + corticosteroids (Group I) and SRL + MMF + corticosteroids (Group II) to TAC + MMF + corticosteroids (Group III) with respect to renal allograft function at month 12 post-transplantation.</brief_summary>
	<brief_title>Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Age &gt; 18 years. Endstage renal disease with subjects scheduled to receive a primary or secondary renal allograft from a cadaveric donor, from a livingunrelated mismatched donor, or from a livingrelated mismatched donor. Unreported HLA values will be considered a match. Women of childbearing potential must have a negative serum pregnancy test before administration of assigned treatment and agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months following discontinuation of assigned treatment. Other inclusions apply. Evidence of active systemic or localized major infection. Known hypersensitivity to SRL or its derivatives, macrolide antibiotics, corticosteroids, TAC or MMF. Multiple organ transplants (i.e., prior or concurrent transplantation of any organs other than renal transplant). Other exclusions apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Kidney Failure</keyword>
	<keyword>Kidney Transplant</keyword>
</DOC>